Tang Huidi, Li Kang, Shi Zhan, Wu Jichao
Department of Pharmacology, Shandong University School of Medicine, Jinan 250012, China.
Cells. 2025 May 16;14(10):729. doi: 10.3390/cells14100729.
Hypertension and diabetes are two common causes of chronic kidney disease. Hypertension can induce renal vascular injury, glomerular damage, podocyte loss, and tubular injury, leading to tubulointerstitial fibrosis. A number of factors influence the regulation of hypertension, among which G-protein-coupled receptors (GPCRs) have been studied extensively because they are desirable targets for drug development. Compared to hypertension, the regulatory effects of GPCRs on hypertensive kidney disease (HKD) are less generalized. In this review, we discussed the GPCRs involved in hypertensive kidney disease, such as angiotensin II receptors (AT1R and AT2R), Mas receptor (MasR), Mas-related G-protein-coupled receptor member D (MrgD), relaxin family receptor 1 (RXFP1), adenosine receptors (A, A, A, and A), purinergic P2Y receptors, and endothelin receptors (ET and ET). The progression of HKD is rarely reversed but can be retarded by ameliorating the hypertensive microenvironment in the kidneys. However, simply reducing blood pressure cannot stop the progression of HKD. Diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD), which is a major cause of morbidity and mortality in diabetes. Many GPCRs are involved in DN. Here, we select some well-studied GPCRs that are directly associated with the pathogenesis of DN to illustrate their mechanisms. The main purpose of this review is to provide an overview of the GPCRs involved in the occurrence and progression of HKD and DN and their probable pathophysiological mechanisms, which we hope will help in developing new therapeutic strategies.
高血压和糖尿病是慢性肾脏病的两个常见病因。高血压可导致肾血管损伤、肾小球损害、足细胞丢失和肾小管损伤,进而引起肾小管间质纤维化。多种因素影响高血压的调控,其中G蛋白偶联受体(GPCRs)因其是药物开发的理想靶点而受到广泛研究。与高血压相比,GPCRs对高血压肾病(HKD)的调控作用尚不十分明确。在本综述中,我们讨论了参与高血压肾病的GPCRs,如血管紧张素II受体(AT1R和AT2R)、Mas受体(MasR)、Mas相关G蛋白偶联受体成员D(MrgD)、松弛素家族受体1(RXFP1)、腺苷受体(A1、A2A、A2B和A3)、嘌呤能P2Y受体以及内皮素受体(ET1和ET2)。高血压肾病的进展很少能逆转,但可通过改善肾脏的高血压微环境来延缓。然而,单纯降低血压并不能阻止高血压肾病的进展。糖尿病肾病(DN)是终末期肾病(ESRD)最常见的病因,是糖尿病患者发病和死亡的主要原因。许多GPCRs参与糖尿病肾病。在此,我们选择一些研究充分且与糖尿病肾病发病机制直接相关的GPCRs来说明其机制。本综述的主要目的是概述参与高血压肾病和糖尿病肾病发生发展的GPCRs及其可能的病理生理机制,希望这将有助于开发新的治疗策略。